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Abstract 
Background: Cannabis products are becoming increasingly diverse, and they vary considerably in 
concentrations of ∆9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Higher doses of THC can 
increase the risk of harm from cannabis, while CBD may partially offset some of these effects. Lower 
Risk Cannabis Use Guidelines currently lack recommendations based on quantity of use, and could be 
improved by implementing standard units. However, there is currently no consensus on how these 
should be measured or standardised across different cannabis products or methods of administration.  
Argument: Existing proposals for standard cannabis units have been based on specific methods of 
administration (e.g. joints) and these may not capture other methods including pipes, bongs, blunts, 
dabbing, vaporizers, vape pens, edibles and liquids. Other proposals (e.g. grams of cannabis) cannot 
fully account for heterogeneity in cannabis products. Similar to alcohol units, we argue that standard 
cannabis units should reflect the quantity of active pharmacological constituents. On the basis of 
experimental and ecological data, public health considerations, and existing policy we propose that a 
‘Standard THC Unit’ should be fixed at 5 milligrams of THC for all cannabis products and methods 
of administration. If supported by sufficient future evidence, consumption of Standard CBD Units 
might offer an additional strategy for harm reduction. 
Conclusions: Standard THC Units have the potential to be applied across all cannabis products and 
methods of administration in order to guide consumers and promote safer patterns of use.  
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Background 
Cannabis is used by an estimated 192 million people worldwide (1). This number may rise further as 
new legal markets in Canada, the USA, Uruguay and elsewhere emerge (2), along with permissive 
stances towards cannabis in illicit markets (e.g. “cannabis social clubs” in Spain and “coffee shops” in 
the Netherlands (3)). Cannabis is also gaining increasing acceptance in modern medicine (4). However, 
there are long-standing concerns about the risks of cannabis use on mental health and cognition (5-7). 
For example, a relatively consistent finding is that greater levels of cannabis exposure are associated 
with an increased risk of adverse outcomes such as the development of cannabis use disorders (8, 9). 
Although there is debate about causality (10-12) the association between cannabis use and risk of 
psychosis strengthens in some individuals with increasing levels of cannabis exposure (13, 14). These 
risks could potentially be minimised by promoting safer patterns of use (15, 16). 
Canada’s current evidence-based (16) Lower Risk Cannabis Use Guidelines (17) include 
recommendations such as: “If you use, choose low-strength products, such as those with a lower THC 
content or a higher ratio of CBD to THC” and “Try to limit your use as much as possible”. No 
recommendations are provided based on quantity of cannabis or cannabinoids used. There is currently 
no consensus on how cannabis use should be measured, which severely limits our ability to provide 
guidance on cannabis use and its consequences (6, 18-20). The National Institute on Drug Abuse 
(NIDA) Cannabis Policy Workgroup  identified the development of standardised units of dose as its 
number one cannabis use research priority (21). The workgroup highlighted the importance of 
accounting for various cannabis products (e.g. herbal, edible, or extract), methods of administration 
(e.g. smoking, eating, vaping and dabbing), the extent to which people use multiple cannabis products, 
and that the active components of cannabis include CBD as well as THC (21).  
 
Heterogeneity in quantities of THC and CBD in cannabis products 
Cannabis products are extremely heterogeneous with regards to THC and CBD1, which may have 
important consequences for their health effects (see Figure 1 and Table 1). Experimental studies of 
cannabis intoxication have shown that THC produces dose-dependent rewarding effects such as feeling 
“high” and relaxed, as well as THC dose-dependent adverse effects including psychotic-like 
symptoms, anxiety and memory impairment (5, 22-24). By contrast, preliminary evidence suggests 
                                                           
1 Here we refer to ‘THC’ as the quantity of ∆9-tetrahydrocannabinol + 0.877*∆9-tetrahydrocannabinolic acid, and ‘CBD’ 
as the quantity of cannabidiol + 0.877*cannabidiolic acid 
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that CBD can produce acute effects that are opposite to THC across a range of cognitive tasks (e.g. 
verbal memory, emotional face processing, response inhibition and visual processing (25)). Co-
administration of CBD may partially offset some of the acute negative effects of THC on several 
cognitive domains and psychopathology symptoms (e.g. verbal memory recall (26, 27), emotional face 
recognition (28) reward processing (29-31) and psychotic-like symptoms (25, 27)).  
Some evidence suggests that long-term exposure to high THC/low CBD cannabis products is 
associated with increased harms. These include severity and treatment rates for cannabis use 
disorders (32-36), risk of developing psychosis (37, 38) and relapse following a first episode of 
psychosis (39). Long-term exposure to CBD, evidenced by toxicological analysis of hair samples, 
was associated with reduced psychotic-like symptoms (40, 41) and protection from hippocampus 
volume loss (42, 43).  
Not all experimental studies have reported protective effects of CBD (44) and some indicate it may 
potentiate certain effects of THC (45, 46). Moreover, exposure to CBD in observational studies may 
be confounded  by other factors, such lower levels of THC in varieties of cannabis that produce high 
levels of CBD (47). Therefore, evidence into the potential role of CBD as a harm reduction strategy 
is still progressing, and further evidence is needed to establish how different doses of CBD might 
influence the effects of THC (15). Additionally, there may be a role of other cannabinoids such as 
delta-9-tetrahydrocannabivarin (THCV) (48) and terpenoids such as limonene, myrcene, α-pinene 
and linalool (49) in moderating the effects of THC. 
 
Heterogeneity in methods of administration of cannabis products  
Cannabis products and methods of administration vary widely and are continuing to diversify (50). 
These include joints, pipes, bongs, blunts, vaporizers, edibles, liquids and others (Table 2). Methods 
of cannabis use vary within and across countries. For example, a multinational study (51) found that 
in Canada, joints were the most popular method of use (43%), followed by bongs, pipes and 
vaporizers (20%, 19% and 13% respectively). In Australia joints were also the preferred route (52%), 
followed by bongs, pipes and vaporizers (25%, 12% and 6% respectively), while in the United States 
the most common method was pipes (48%) followed by bongs, joints and vaporizers (19%, 14% and 
11% respectively) (51). Dabbing (a method specifically used for cannabis concentrates) has become 
relatively widely used in new legal markets in the United States, with concentrates representing 
approximately 12% of all sales in Washington State (52). Edible and liquid cannabis consumption 
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has also risen in legal markets, representing approximately 10% of sales in Washington State (52). 
Distinct routes of cannabis use are associated with differences in the duration and the intensity of 
intoxication. The absorption of cannabinoids is more variable and slow after oral administration than 
for inhaled administration, which limits the ability to titrate effects based on blood cannabinoid 
levels (53). Overall, the high and increasing heterogeneity in methods of administration, dosage and 
related intoxication effects will continue to present challenges for the development of standardised 
guidelines that outline practical recommendations for safer patterns of use.  
 
Previous arguments for standard cannabis units  
We are not the first to discuss the concept of standard cannabis units (Table 3). Existing proposals 
have been based on the concept of ‘Standard Joints’ (54, 55), grams (56) and multiple types of 
administration (55, 57). A key study in Barcelona (54) tested the contents of peoples’ joints and 
equated the ‘Standard Joint Unit’ to the quantity of THC, price, and weight of cannabis from these 
joints. CBD was found in joints containing cannabis resin but not herbal cannabis, and was not included 
in the Standard Joint Unit. Advantages of this approach include its reference to a commonly used 
method of administration in Europe (51) which may be easily applied in research and clinical settings, 
and validation against problematic use (58). However, the Standard Joint Unit does not capture other 
methods of use. Additionally, the extent to which it reflects a standardised dose may be influenced by 
regional and individual variation in joints (59, 60) and changes in THC concentrations in cannabis 
over time (61, 62). 
Grams of cannabis have been proposed as a standardised measure of quantity (56) but these do not 
account for variation in THC. For example, based on information from the UK in 2015/2016 (Table 
1) a typical gram of cannabis concentrate might contain 26 times more THC than a typical gram of 
outdoor-grown herbal cannabis (780 milligrams THC compared to 30 milligrams THC). Similarly, a 
litre of vodka (40% alcohol by volume) would not be considered equivalent to a litre of beer (5% 
alcohol by volume), as it contains 8 times more alcohol (320 grams compared to 40 grams) and 
therefore carries an increased risk of harm.  
A recent standard cannabis unit proposal addresses both THC and CBD by quantifying their relative 
ratio (63). Hindocha, Norberg and Tomko classified cannabis into three THC/CBD types: high 
THC/low CBD (.25g = 1 unit), equal THC/CBD (.5g = 1 unit), or low THC/high CBD (.75g = 1 unit) 
(63). However, these fixed THC:CBD ratios may not be sensitive to the varying levels of THC and 
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CBD found in cannabis products. For example, cannabis concentrates and outdoor-grown herbal 
cannabis in the UK both contain a high level of THC relative to CBD. Therefore, a gram of each of 
these might be considered equal, despite concentrates containing ~26 times more THC than outdoor-
grown herbal cannabis.  
The measurement of standard cannabis units is hindered by variation in cannabis products, their THC 
and CBD content, and different methods of administration. Alcohol research has faced similar issues 
during the development of standard alcohol units, as there is considerable heterogeneity in the types 
of drink consumed and the amount of alcohol they contain. Therefore, alcohol units may provide a 
useful framework to inform the development of objective, standardised cannabis units. Alcohol units 
are defined by the number of grams of alcohol (e.g. in the UK, 1 unit = 8g alcohol). Although the size 
of an alcohol unit varies across different countries, the use of a common metric (i.e. grams of alcohol) 
has allowed standard alcohol units to be applied across a wide range of alcohol products.  
 
A new proposal for Standard THC Units 
We argue that for cannabis, as for alcohol, standard units should be based on the quantity of active 
pharmacological products. The primary psychoactive constituent of cannabis is THC. Therefore, 
standardised doses of THC should form the basis of ‘Standard THC Units’ rather than other proxies 
of cannabis exposure (e.g. grams, joints). It is important to emphasise that dose (milligrams of THC) 
is different from concentration (% of THC) and the former should be used to inform Standard THC 
Units. This information could help to guide consumers on the number of standard doses each product 
contains at the point of sale (Figure 2). Evidence from Canadian respondents suggests that labels listing 
the number of doses on edible products were more effective at conveying information than those listing 
THC milligrams alone (64). As with other information on product labels, this information should be 
as accurate as possible while accounting for variation within a product. Qualitative data from the US 
suggests that serving size statements on edible products were considered useful as a “baseline” for how 
much that product might affect the user (65). It was also reported that serving size suggestions would 
be easier to comprehend if they were made equivalent to the number of “hits” on a joint rather than 
simply listing the number of milligrams (65). This suggests that there may be value in the concept of 
a Standard THC Unit and applying it to multiple cannabis products. Labelling of Standard THC Units 
could be incorporated into existing Lower Risk Cannabis Use Guidelines (17) such that they can 
provide specific recommendations based on quantity of use. Standard THC Units could be used to 
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inform specific policies such as minimum unit pricing, which might be especially effective at reducing 
harmful levels of consumption on the basis of alcohol research (66).  
A major challenge for Standard THC Unit implementation is understanding how they can be applied 
across different products and routes of administration. This is particularly important when 
considering inhaled and oral administration, which have not been accounted for in previous 
proposals for standard cannabis units (Table 3). There are important differences in bioavailability 
and time-concentration profile of inhaled and oral THC. Bioavailability following inhaled THC 
typically ranges from 10%-35% and is influenced by factors such as the number, duration and 
spacing of inhalations as well as side stream smoke (67). Oral administration is characterised by 
significant first pass metabolism in the liver, lower bioavailability (2-14%) (67), a slower onset of 
absorption, lower peak concentrations and longer elimination when compared to inhaled cannabis, as 
well as higher 11-nor-9-carboxy-THC concentrations (68). It has been proposed that 1 milligram of 
THC in oral form might be considered pharmacokinetically equivalent to 5.71 milligrams of THC in 
inhaled form (69).  However, these calculations were not based on the subjective effects of THC. 
Such effects have a slower onset and longer duration following oral versus inhaled administration 
(70, 71). However, the peak level of subjective effects has been found to be comparable between 
these routes (Ohlsson et al., (70); infrequent users in Newmeyer et al. (71)). Peak subjective effects 
may be an important component of what constitutes a Standard THC Unit (i.e. the maximum level of 
‘stoned’ or ‘good drug effect’). Therefore, these findings suggest that the same sized THC unit could 
be applied across oral, vaporized and smoked routes of administration (71).  
We acknowledge that it will not be possible to achieve complete equivalency in the subjective effects 
of a Standard THC Unit across different routes of administration (as with any conversion across 
routes). Subjective effects may be influenced by variation in cannabis use behaviours (such as 
smoking topography (72)) and other factors such as tolerance (71). There are also differences in the 
health effects of using different methods of cannabis administration (e.g. smoking being most 
harmful) as recommended by current Lower Risk Cannabis Use Guidelines (16). However, using the 
same standardised THC unit across different products could have significant advantages in terms of 
acceptability, feasibility and product labelling. For example, herbal cannabis can be consumed in 
multiple ways including smoking, vaping and eating and many others methods (Table 2). If the size 
of Standard THC Unit differed for each of these methods, consumers may it difficult to understand 
and estimate their unit consumption, especially if they use cannabis in a variety of ways. Labelling 
multiple unit sizes on a single package might create complex labels that are difficult for consumers to 
comprehend. This contrasts with the principle that labelling on cannabis products should be clear and 
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require minimal numeracy to understand (73). Therefore, labelling each cannabis product with a 
fixed number of Standard THC Units – which apply to all methods of use – could allow standard 
units to be easily implemented and better understood by consumers. 
Another major challenge is establishing how many milligrams of THC should form one Standard THC 
Unit. Experimental studies have shown that inhaled and oral doses of THC ranging from approximately 
2 to 8 milligrams can have intoxicating effects without producing severe adverse responses among 
infrequent users (22, 74-76). Given that frequent cannabis users can develop tolerance to the effects of 
THC (77) they may consume higher doses during typical use. However, 8 milligrams vaporized THC 
was found to produce robust subjective, cognitive and psychotomimetic effects in daily cannabis users 
(28, 44). This approximate dose range (2 to 8 milligrams) is supported by ecological data from a study 
in Barcelona (54) which estimated that a Standard Joint Unit should contain 7 milligrams of THC, on 
the basis of analysis of joints containing herbal cannabis or cannabis resin. 
From a public health perspective, it may be considered advantageous to choose a standard THC unit 
that is lower than the average level of consumption (73). This could encourage people to consume 
less THC, as reducing the serving size of an alcoholic drink has been found to lower alcohol 
consumption both in experimental and real-world settings (78). A low dose could also reduce the 
chances of an excessive and/or unpleasant response to a single THC unit in naïve volunteers. For 
example, in a study administering 10 milligrams of oral THC people to people with minimal 
exposure (less than 15 lifetime occasions of use), 33% of the sample experienced a severe reaction 
such as paranoia (79). Another study of volunteers reporting no cannabis use in the past month found 
that 12% of the sample vomited after receiving an inhaled dose of 25mg THC (24). 
The risk of unintentional or excessive dosing is especially high for edible products, due to the slow 
onset of effects which limits ability to titrate effects. A study in Colorado found that ingestion was 
responsible for 74% of all paediatric regional poison centre admissions for cannabis (80). At the time 
of writing, the maximum quantity of THC that can be sold in a single serving of edible is 5 
milligrams in Alaska and Oregon and 10 milligrams in Colorado and Washington (81). Regulations 
for Canada include a limit of 10 milligrams THC for edibles (per package) and 10 milligrams THC 
for ingested extracts (per capsule or dispensed amount) (82). On the basis of experimental and 
ecological data, public health considerations, and existing policy we propose that a Standard THC 
Unit should be fixed at 5 milligrams of THC for all cannabis products and methods of 
administration. In terms of edible products, this would allow the same unit size to be applied across 
different regions within current legislation (half of the maximum serving size in Colorado, 
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Washington and Canada; the maximum serving size in Alaska and Oregon). The same 5 milligram 
THC unit could be applied to other products (Figure 1) including pre-rolled joints (Figure 2) to guide 
consumers on recommended dosage. We argue that a Standard THC Unit of 5 milligrams has the 
potential to be acceptable as meaningful standard dose, while being low enough to minimise the risk 
of adverse effects after consuming a single unit. Standard THC Units could be incorporated into 
Lower Risk Cannabis Use Guidelines (17) to permit quantitative recommendations for safer use. 
 
Remaining challenges 
Accounting for CBD may also be important as varying levels of CBD are present in cannabis and 
may influence its health effects (15). Canada’s Lower Risk Cannabis Use Guidelines currently refer 
to CBD in terms of the CBD:THC ratio (17). However, the evidence for CBD protecting against 
THC harms is preliminary at present and further research is needed strengthen the evidence and 
identify dose-response effects (15). If supported by adequate evidence, consumption of CBD units 
might be recommended in future as a strategy to mitigate the harms of THC unit consumption. Such 
guidelines might be considered acceptable to people who use cannabis if CBD units could mitigate 
THC harms without compromising the ‘high’ they seek, as suggested by some research (15). A 
recent survey of people residing in US states where recreational cannabis use is legally sold found 
that CBD content was consistently rated as the one of the most attractive attributes of cannabis 
products (83). Evaluating the health impact of CBD in cannabis should be a priority given its 
significant interest to consumers. 
Introducing Standard THC Units to public health guidelines may not be feasible in jurisdictions where 
cannabis use is prohibited. Illicit markets can also create barriers for research on standard units, such 
as participant recruitment, drug administration and collection of samples. However, if a consensus is 
reached on which metrics should be used to define Standard THC Units in legal markets, these “ideal 
criteria” could be used to update and harmonise international research methodology and clinical tools. 
Moving towards the quantification of active pharmacological products (THC and CBD) could improve 
our understanding of cannabis use and its consequences. Some researchers are already using 
milligrams of THC as a metric to estimate long-term THC exposure (84). Dosage of THC and CBD in 
milligrams can be estimated by combining information on the (i) quantity of cannabis product used, 
(ii) the type of product used, and (iii) its estimated THC and CBD concentration. Precision may be 
increased by asking people to physically estimate the amount of cannabis they use with cannabis 
material (85) or a substitute (85-87). The increasing number of studies quantifying THC and CBD 
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concentrations in illicit cannabis markets (61, 62, 88-94) and the use of pictorial aids (Figure 1) during 
substance use assessments (95, 96) may help to improve estimation of THC and CBD exposure in 
jurisdictions where cannabis use is illegal.   
 
Conclusion 
Standardising dosage using fixed quantities of THC could allow the same units to be applied across 
different cannabis products and routes of administration. Multidisciplinary debates in the 
international community of researchers, policy makers, clinicians and people who use cannabis will 
be instrumental for gaining consensus on standard units and their inclusion in lower risk guidelines.  
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Figure 1: Heterogeneity in cannabis products: (A) Outdoor-grown herbal cannabis or ‘imported 
herbal cannabis’; (B) Indoor-grown herbal cannabis or ‘sinsemilla’; (C) Cannabis resin or ‘hashish’; 
(D) Cannabis concentrates used for ‘dabbing’; (E) Vape pen containing cannabinoids; (F) Edible 
gummy bear containing cannabinoids.  
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Figure 2: A package containing pre-rolled cannabis joints sold in Canada. Labels include the total 
quantity of THC (25.1mg) and CBD (41.3mg) per joint. No information is provided on the number of 
standard doses each joint contains. In order to guide consumers, labels could include additional 
information such as “Each unit [joint] contains five standard doses of THC”.  
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Table 1: Heterogeneity in typical concentrations of 9-tetrahydrocannabinol (THC) and cannabidiol 
(CBD) across cannabis products and countries 
 
 
 
 
 
Table 2: Heterogeneity in methods of administration of cannabis products 
Method Route Combined with tobacco 
Joint Inhaled, combusted Yes/No 
Pipe Inhaled, combusted Yes/No 
Blunt Inhaled, combusted Yes 
Bong Inhaled, combusted Yes/No 
Dabbing Inhaled, combusted Yes/No 
Vaporizer Inhaled, vaporized Yes/No 
Vape pen Inhaled, vaporized Yes/No 
Edible Oral No 
Liquid Oral No 
 
 
 
 
 
Country, year Reference Outdoor-grown herbal Indoor-grown herbal Resin Concentrates 
USA, 2017  (61) 9% THC, <1% CBD 18% THC, <1% CBD 46% THC, <1% CBD 56% THC, <1% CBD 
Australia, 2010-12  (88) 15% THC, <1% CBD 19% THC, <1% CBD - - 
UK, 2015-16  (92) 3% THC, <1% CBD 14% THC, <1% CBD 6% THC, 2% CBD 78% THC, <1% CBD 
Netherlands, 2015  (90) 5% THC, <1% CBD 15% THC, <1%CBD 18% THC, 8% CBD - 
France, 2016 (89) - - 23% THC, 4% CBD - 
Denmark, 2017 (94) - - 23% THC, 6% CBD - 
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Table 3: Existing proposals for standard cannabis units/standardised measures of quantity 
First author, year  Reference Standard 
cannabis unit 
Description Strengths: accounts for Limitations: does not account for 
Wetherill, 2016  
 
(56) Gram Years Number of daily grams consumed, multiplied by 
years of cannabis use  
Some different methods of 
administration 
 
Variation in quantities of THC and CBD 
Casajuana-Kögel, 
2017  
(54) Standard Joint 
Unit 
1 unit = 1 joint, or .25 grams cannabis, or 
 7 milligrams THC, or 1 Euro. 
The most common method of 
administration in Europe 
 
Variation in quantities of THC and CBD and 
other methods of administration 
Ziesser, 2012  (55) Standard Joint 1 standard joint = 0.5 grams cannabis,  
10 puffs or 5 bong hits, or 
5 pipe hits 
 
Some different administration methods 
and/or number of puffs 
 
Variation in quantities of THC and CBD and 
other methods of administration 
Norberg, 2012 (57) Cannabis Unit 1 unit = 0.25 grams cannabis, or 
1 paper joint or 1 blunt, or 
2 skinny paper joint/blunt , or 
3 cones/water pipes/bongs/bucket bongs 
 
Some different sizes of joint and 
methods of administration 
Variation in quantities of THC and CBD and 
other methods of administration 
Hindocha, 2017  (63) THC/CBD ratios High THC & low CBD (e.g. 1 unit = .25 gram) 
Equal THC & CBD (e.g. 1 unit = .50 gram)  
High CBD & low THC (e.g. 1 unit = .75 gram)  
Some variation in THC/CBD ratios Variation in quantities of THC and CBD 
  
 
